Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.
Comment: Migration of unmigrated content due to installation of a new plugin
Monday
 To do's
To Do's 
  •  make BCR enzyme stock
  •  digest, gel:
    •  pENTR mKate
    •  hEF1a:CD79B-TCS-G4
    •  hEF1a:Gal4VP16
  •  LR EGSH:mKate, hEf1a:VgEcR-2A-RXR, hEF1a:mKate
  •  transform:
    •  TRE:syk because we don't have a midi
    •  Re-transform CD79A-TCS-G4 and CD79B-TCS-G4 SDM Golden Gates 
  •  pick more CD79A linker colonies (all old DNA is not good)
  •  pick CD79A SDM colony 
:
  •  Midiprep (from freezer)
    •  S9TEV
    •  B15T15
  •  Golden Gate
    •  B9T9
    •  B15T9
  •  LR
    •  hEF1a-CuO:Gmab H
    •  hEF1a-CuO:Gmab L
    •  hEF1a-CuO:CD79A
    •  hEF1a-CuO:CD79B
    •  hEF1a-CuO:Lyn
  •  Digest all of the Syk-TEVp and Syk-tTEVp midis just to be sure (since there's an internal cut site that didn't get read in sequencing)



 pick hEF1a:CymR, hEF1a-CuO:mKate, CMV5-CuO:mKate

 

CMV5-CuO 715:

hEF1a-CuO 715:09

CymR-CuO 710:09

Geneious To Do List:
  •  Antibody cloning for chicken lysozyme - Kathryn 
  •  hef1a sequencing primers

 

BCR 2.0 To Do

Sequencing account information:

^^^Email: bcrpeeps@mit.edu

^^^Pass: grapefruit

 

 

## Digest tTEVp and TEVp midis just to be sure (since there's an internal cut site)

Non-Lab To Do's 
  •  Bug Brian about ordering antibody testing supplies
Higher Level To Do's:
  •  Decide on other antigen-variable regions we want to test  
  •  Other experimental planning (on experimental page)
  •  Parts list (excel sheet detailing specs/locations of parts)
  •  How do we do site directed mutagenesis?
  •  Literature research: 
    •  kozak sequences for heavy and light chains and CD79s
    •  truncated TEVp
    •  other antigens to detect using BCR (we were thinking of small molecule detection)
    •  inducible promoters (we were considering LacI - an inducible repressor - but we want to look into other options first) 
  •  Cloning planning 
    •  hEF1a:Syk-pTet:mRFP-TEVp
    •  variable region 
  • Is gantenerumab proprietary and can we actually publish with it?